Rich has a proven track record of leading global businesses, driving sales execution and building commercial organizations to drive growth. Prior to joining RTI, he led the turnaround of Alphatec Spine from December 2016 through December 2018. As a director and CEO, he strengthened the organization’s competencies, redirected the portfolio with 12 new products and laid the foundation for focused innovation and growth. Prior to Alphatec Spine, Rich was President of Upper Extremities at Wright Medical Group, N.V. Rich has held sales leadership positions at Tornier, NuVasive and DePuy Spine earlier in his career.
“This is an important appointment that adds a globally recognized leader to the helm of our spine segment at RTI,” said Camille Farhat, president and CEO, RTI. “Terry has a deep commitment to growth and innovation, as well as exceptional relationships with clinical thought leaders in our market. Our spine business is in the early stages of what we believe is a longer-term transformation with tremendous opportunities ahead. We believe Terry’s leadership will help accelerate the execution of our Novel Therapies commercial channel and multiple product launches planned for 2020.”
“RTI has built an under-estimated spine business,” said Rich. “We believe pursuing a growth strategy of investing in differentiated products and building scale is a formula for accelerating growth. RTI has developed and secured unique, data-supported products and is building a Novel Therapies commercial channel that should accelerate these products to standard of care. We believe we have an incredible opportunity to be the partner of choice for independent distributors and surgeons focused on growth and delivering the quality, safety and outcomes that spine patients expect and deserve.”
Olivier Visa has been promoted to president of Global OEM. Visa joined RTI in October 2017 as vice president of OEM and has spearheaded the positive performance of this business segment within RTI. Under his leadership, the OEM segment has earned a solid market position serving leading medical technology companies that operate in a diverse set of end markets with attractive growth profiles. Over the past two years the business has returned to growth, driven operational excellence and delivered significant predictable recurring EBITDA.
“I am extremely proud of our RTI team for building an OEM segment that has delivered stable revenue and EBITDA growth over the past two years, while keeping our customers at the center of all we do,” said Visa. “Our growth trajectory is rooted in our deep and unique technical expertise across metal, tissue and biologic products and our broad range of services that span from design and development to manufacturing and fulfilment. I look forward to our continued growth, the expansion of our customer partnerships and the fulfillment of our deep product pipeline.”
Both Rich and Visa will report to Camille Farhat.